-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IPbAGVHA38CJFOtwsBJ8BQwe4q0j60tw6ZGb40KombBSi6oPOHnZjyLYWkr446DV
 tAzDF5fN8f6dG2vk2NEzeA==

<SEC-DOCUMENT>0000950144-08-006371.txt : 20080812
<SEC-HEADER>0000950144-08-006371.hdr.sgml : 20080812
<ACCEPTANCE-DATETIME>20080812090152
ACCESSION NUMBER:		0000950144-08-006371
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080811
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080812
DATE AS OF CHANGE:		20080812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		081008213

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g14708e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): August&nbsp;11, 2008</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>








<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other jurisdiction of</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employee Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>incorporation or organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2 below).
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4&#169; under the Exchange Act (17 CFR
240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<!--TOC-->
<!--/TOC-->





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to
time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>
<!-- link1 "Item&nbsp;2.02 Results of Operations and Financial Condition" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;11, 2008 we issued a press release reporting our quarterly results of operations for
the period ended June&nbsp;30, 2008. A copy of the press release is attached to this Current Report.
</DIV>
<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99 &nbsp;&nbsp;&nbsp; Press Release
</DIV>
<!-- link1 "SIGNATURES" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: August&nbsp;12, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>g14708exv99.htm
<DESCRIPTION>EX-99 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g14708g1470800.gif" alt="(GEOVAX LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Melanie Nimrodi, Media Contact</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.546.3508</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u>mnimrodi@frbir.com</u></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At the Company:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert McNally / Jennifer Nelms</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">404.727.0971</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GeoVax Labs, Inc. Announces Six Month Financial Results<BR>
and Provides Operational Update</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA, Ga., August&nbsp;11, 2008 &#151; </B>GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based,
biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus) and other infectious agents , today announced its financial results and
provided an operational update for the six months ended June&nbsp;30, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Financial Results for the Three Months and Six Months Ended June&nbsp;30, 2008</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company recorded a net loss of $1,284,352 for the three months ended June&nbsp;30, 2008, compared to
$1,333,126 for the same period in 2007. For the six months ended June&nbsp;30, 2008, the Company&#146;s net
loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset
by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively,
related to the Company&#146;s grant from the National Institutes of Health in support of its HIV/AIDS
vaccine development activities. As of June&nbsp;30, 2008, the Company reported cash balances totaling
$3,133,839.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summarized financial information is attached. Further information concerning the Company&#146;s
financial position and results of operations are included in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Management Commentary</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Robert McNally, GeoVax&#146;s President &#038; CEO, commented, &#147;We are pleased with our six month financial
results, including our operational expenses and cash position. Our operational expenses are minimal
for a company of our size and stage of clinical trial development. We are particularly pleased
with the financing strategy provided by the $10&nbsp;million common stock purchase agreement with Fusion
Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2
preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the
therapeutic trial in HIV infected and drug-treated humans.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;McNally continued, &#147;We are also progressing past a signed letter of intent and toward
completion of a manufacturing license with Vivalis S.A., a French biopharmaceutical company.
Vivalis has a manufacturing platform technology for the MVA portion of the GeoVax vaccine that will
significantly improve the production capabilities for the vaccine as the company looks toward
worldwide use of this important therapeutic product.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Operational Highlights &#151; 2008:</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In January&nbsp;2008, GeoVax was recognized by Georgia Bio, the state trade organization, as a
2007 &#147;Deal</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>More</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax, Inc.<BR>
Add 1</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>of the Year&#148; award winner for receipt of the $15&nbsp;million IPCAVD grant from the
National Institutes of Health (NIH). The award was presented at Georgia Bio&#146;s annual awards
dinner on January&nbsp;24, 2008. This grant is believed to be one of the largest grants of its kind
to be awarded in the last fiscal year.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In February&nbsp;2008, GeoVax announced the addition of company co-founder Dr.&nbsp;Harriet Robinson
to its staff as Vice President of Research &#038; Development. Dr.&nbsp;Robinson is known worldwide for
her outstanding work on retrovirus biology and a pioneer of DNA vaccines with special emphasis
on HIV/AIDS. Dr.&nbsp;Robinson has published extensively on HIV/AIDS vaccine research, with more
than 150 referred scientific journal publications, 50 monograph reviews and six book chapters
authored. She has consulted for the U.S. National Institutes of Health, the U.S. Food and Drug
Administration, the Bill and Melinda Gates Foundation and the World Health Organization. She
served as Chief of Microbiology and Immunology at Emory University&#146;s Yerkes National Primate
Research Center and was an Asa Griggs Candler Professor of Microbiology and Immunology at the
Emory University School of Medicine. Dr.&nbsp;Robinson is the inventor of GeoVax&#146;s HIV-1 AIDS
vaccine technology and co-founder of GeoVax Labs, Inc.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During February&nbsp;2008, GeoVax announced that its Vaccine was only the 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> AIDS
Vaccine moving forward into Phase 2a human trials by the HIV Vaccine Trials Network (HVTN), a
network supported by the National Institutes of Health (NIH). GeoVax has completed three Phase
1 human trials evaluating its HIV/AIDS vaccines with excellent results and has two additional
human trials undergoing data analysis. Due to promising results from these five trials, GeoVax
is pushing forward with plans for the critically important and larger Phase 2 human trial.
GeoVax&#146;s Phase 2a human trial is designated as Protocol # HVTN 205.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In March&nbsp;2008, GeoVax named Dr.&nbsp;Robert McNally as its President and CEO, effective April&nbsp;1,
2008. Former President/CEO and company co-founder Don Hildebrand remained as Chairman of the
GeoVax Board of Directors and continues to be heavily involved in company development, growth
and expansion plans in the AIDS vaccine arena. Dr.&nbsp;McNally has been a member of the GeoVax
Board of Directors since 2006 and was previously a co-founder and CEO of Cell Dynamics LLC and
Cell Design LLC companies specializing in GMP processing of human cells for pharmaceutical and
therapeutic applications. Dr.&nbsp;McNally was also co-founder and Sr. Vice President of Clinical
Research for CryoLife, Inc., a pioneering company in transplantable human tissues. He has had
previous experience as European Regional Manager for Intermedics International, Inc., and
European Marketing Manager for Pacesetter Systems-Europe, Ltd., in the U.K. Dr.&nbsp;McNally serves
as a member of the advisory boards of the Petit Institute for Bioengineering and Dupree
College of Management at the Georgia Institute of Technology. He is an elected fellow of the
American Institute for Medical and Biological Engineering, and is a past Chairman for the
Georgia Biomedical Partnership, a trade association, and is recipient of the 2004 Biomedical
Industry Growth Award for the State of Georgia. Dr.&nbsp;McNally has a Ph.D. and MSE in
Bioengineering from University of Pennsylvania and an electrical engineering degree (B.E.E.)
from Villanova University.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During April and May&nbsp;2008, the Company raised $1,365,000 in capital through a private
placement of its common stock and warrants sold to individual accredited investors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In May&nbsp;2008, the Company entered into a $10&nbsp;million common stock purchase agreement with
Fusion Capital Fund II, LLC, a Chicago based institutional investor. Under the agreement, the
Company may sell from time to time up to $10&nbsp;million of its common stock to Fusion Capital
over a 25-month period, following approval of the Company&#146;s registration statement by the
Securities and Exchange Commission (declared effective on July&nbsp;1, 2008). GeoVax will use the
proceeds to further its developmental
HIV/AIDS vaccine, expected to enter Phase 2 human clinical trials later this year and its
upcoming</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>More</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax, Inc.<BR>
Add 2</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>planned therapeutic trials. The Company has the right to sell shares of its common
stock to Fusion Capital from time to time in amounts ranging from $80,000 to $1&nbsp;million,
depending on certain conditions, up to $10&nbsp;million in the
aggregate. The purchase price of the shares will be based on the prevailing market prices of the Company&#146;s shares at the time of
sales without any fixed discount, and the Company will control the timing and amount of any
sales of shares to Fusion Capital. There are no negative covenants, restrictions on future
financings, penalties or liquidated damages in the agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In June&nbsp;2008, following approval by the Company&#146;s shareholders, GeoVax changed its state of
incorporation from Illinois to Delaware.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In July&nbsp;2008, the Company provided an operational update on the Company&#146;s progress towards
entering Phase 2 preventative human clinical trial testing and plans to proceed into
therapeutic human trials with its AIDS vaccine. Five successful human trials evaluating GeoVax
AIDS vaccines had previously been reported. Following are highlights of the announcement:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B><FONT style="font-family: Wingdings">&#167;</FONT></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Phase 2 Preventive Trial &#151; </B>The Company&#146;s planned Phase 2 trial, which will be conducted
by the U.S. NIH-supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy
volunteers from the United States and South America to further evaluate the safety and
immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection
with the HIV virus). In Phase 1 trials, both 1/10th<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>dose and full dose
administrations of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was
required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The
larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the
full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing
AIDS should they be exposed to the virus. The planned Phase 2 human clinical trial is
currently scheduled to start early this fall, subject to FDA approval.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B><FONT style="font-family: Wingdings">&#167;</FONT></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Planning for Therapeutic Human Trials &#151; </B>GeoVax reported summary data from a pilot study
on therapeutic vaccination in simian immunodeficiency virus (SIV)&nbsp;infected non-human
primates with the SIV prototype of GeoVax&#146;s AIDS vaccine. In this small pilot study,
conducted by Dr.&nbsp;Rama Amara at Emory University, two non-human primates were infected with
SIV. At 12&nbsp;weeks post SIV infection, conventional anti-viral drug therapy was given to the
primates to reduce the viral RNA infection levels to very low levels creating a non
progressor status for the primate. Then the GeoVax vaccine was administered. Six weeks
following the final vaccination, anti-viral drug treatment was stopped and the animals were
monitored to determine whether the vaccine could control the SIV infection during the
absence of the drugs. Data from the study revealed outstanding results with the vaccine
controlling the infection with 1000 times reduction in viral levels in one primate and 100
times in another primate. The excellent control of the virus infection in the absence of
drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells
that are found in the rare individuals who spontaneously control their HIV infections.
Based on these excellent results, planning for a therapeutic trial in infected and
drug-treated humans has been initiated. The intent of therapeutic vaccination will be to
&#147;control&#148; HIV virus levels in infected individuals to very low levels thus blocking the
development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines
would lead to reduction in the use of costly anti-HIV medications and their often harmful
side effects. Further, GeoVax is currently engaged in negotiations with a NIH sponsored
trial network to administer, conduct and co-sponsor GeoVax&#146;s therapeutic human trial
program. Management expects to receive approval for undertaking formal protocol development
in the near future and will report more detailed plans accordingly.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <Td width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD colspan=2>In July&nbsp;2008, GeoVax and Vivalis S.A., a French biopharmaceutical company that provides
innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines
and proteins, jointly</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>More</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax, Inc.<BR>
Add 3</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>announced the signing of a letter of intent (LOI)&nbsp;for joint
collaboration and commercial license on the use of Vivalis&#146; EBx<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>technology, to
manufacture the MVA component of the GeoVax HIV-1 vaccine. This agreement between GeoVax and
Vivalis creates a worldwide strategic partnership between Vivalis and GeoVax, designed to
combine Vivalis&#146; cutting-edge vaccine manufacturing technology with GeoVax&#146;s promising HIV
vaccine. The breakthrough manufacturing technology developed by Vivalis, through further
development collaboration with GeoVax, will create a new standard for manufacture of the MVA
component of GeoVax&#146;s HIV/AIDS vaccine, making present manufacturing technologies which have
limited production capabilities, less competitive. Vivalis&#146; EBx<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>manufacturing
platform, with its increased effectiveness, superior quality and reliability, will speed time
to market MVA vaccine product availability in ample quantities to meet sizeable demand and
expectedly at a lesser cost. Vivalis&#146; vaccine manufacturing technology is based on a duck
embryonic stem cell substrate platform. Specifically, the EB66<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>cell line provides
continuous growth from a fully characterized frozen cell bank, without necessitating
fertilized embryo extraction and processing, as with present chicken cell based technologies.
Furthermore, the EB66<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>cell line can be grown in suspension (without the cells
attached to the surface of the growth vessel) and can be scaled up for growth in giant
bioreactors (a cutting edge industrial method) for large scale production of the MVA viral
vaccine.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>More</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax, Inc.<BR>
Add 4</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Six Months Ended</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">June 30,</TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">June 30,</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">376</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">976</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">759</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">701</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,363</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">913</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">918</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">650</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,050</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,677</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,351</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,986</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,963</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(1,284</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(1,333</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(1,967</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(1,920</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income (loss)&nbsp;per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.<BR>
Condensed Balance Sheet Information<BR>
(amounts in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Dec. 31,</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2008</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">2007</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,990</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">138</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,041</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,272</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,031</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">128</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">352</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">598</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,660</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,648</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,246</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">743,415</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">731,628</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>More</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Geo Vax, Inc.<BR>
Add 5</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About GeoVax Labs, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s HIV/AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent
Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person
ever become infected. GeoVax HIV/AIDS vaccines also may be effective as therapeutics (treatment of
people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected
individuals are in the planning stage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at
Emory University&#146;s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease
Control and Prevention (CDC)&nbsp;and the GeoVax team.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health &#091;NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by <B>NIAID</B>, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007. www.geovax.com
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Safe Harbor Statement: </I></B><I>All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions as of the
date of this press release and are subject to numerous risks and uncertainties which could cause
actual results to differ materially from those described in the forward-looking statements. Risks
and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture
these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be
determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in
humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed,
GeoVax can raise the required capital to complete development of its vaccines, there is development
of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters discussed in this news
release are forward looking statements involving certain risks and uncertainties including, without
limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --># # #<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14708g1470800.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14708g1470800.gif
M1TE&.#EA)P$R`.8``(:8K>7HZ[K)U&Z$E\C3W*2WQI6SQOO]Z_[^^2,Z896H
MO.KS]#A6>-;<XN?N\"Q&<UEWE$ADA<+-UO'S]:2SOLG9X&9YE/W^]3E=A$5<
M=V>(HXBENK7%SOS]\/;Y^GF3IMWDZG6)H?[^_"I`62M#;?[^_OO]Y+"YQ=+7
MW28_;3)-=:S(TJO`R#)+:?WY^2Q);BQ"9'N8L=KAYB5"9-SH[/'W^/GZ^E)K
MAUV$I%ERCNGTZ_[\_=?DW=/@X_WZ^VR7M?3Y]5M^F?K\_'J%E$]TE;W/VD)H
MD2Q(8\G@XVR/J-3CZCI2;?S\_+C4VIBMN(J?K\#%STA[H2]1>%-NE$!;?DQP
MC/O\^8.2H_C[_-7GZJ2^SOOV^?W^_K;/RB9&;7N?L][JY.WN\I6EL[:_S_;V
M]_S]_N#J[_#R\?[\_OO]]F>`G?WZ^"U.;7N.K?W[\B='9&*.KOC\\_GY\J"L
MO3YB?_KX]R`^9?W]^][?YHZ@N=/KX/CZZ_7WY<K/U8!^G____R'Y!```````
M+``````G`3(```?_@'^"@X2%AH>(B8J+C(V,(@T$!!4>CI:7F)F:FYR=GI^@
MH:*"!'0M+3&5HZNLK:ZOL+&R04='$%NRN;J[O+V^F`PI*D6_Q<;'R)D+/0TK
M6@8*!E<A`VH6UQ9303E$$-PY%FKB:B'E&P9:*Q5(#C4EABPI,`/)]?;WK&4U
M"PX@!,\*IJFI8D3%DA9+I#!0\:+6"Q)O6AQ)\8;$C#=O$LRXJ/'-18]OO&!\
M\(#-PQ<JZ$0(,D!!#0@)6E#`XV""D'?X<NK<^:>$$#)A>JPH\"1)D"I4%JIH
M\7`CB18;*QX\\J*%BJM+ET0P0H1(#@@0O((E8J0*63H%E\!@(W&C%SMV_S`"
MZ/)@Q@T.2Z:H>:)`BX2:'N[P'$Q85@DS1>;$,,+&"PDO%RW.@.'E"(D4(TBF
MP&!DP!`_`)QH*8)"A@,Y@D0(/N0#YR$L861,:E(``(`0%HI(&9%"3)L9E1,<
M:9R"09`G!1I@*<R\.:<="PCDT8!!2HH4D.TDL+/Q2((7+V`\4!%AP)4K6@AD
MT5''D0C7?^Z(.'3G0J$=@K#PDR`RP8HO&)#T@$5'/'!$"R,L85X!!%CAW(,0
M%D)&%GFH0<55(GF1P@P;8N<%>%00$<,<'/00P!EDV&`%`B7`E\A[A*PQ7T^(
ME##C(#?^4<,'(U!EA0<3A($'!Q2(<440*2!$%?\)#$BAP@T?))=CA%0FPT4-
M#A0A1A!)O;#1EV_-\()6(0!`@00@!!"&*H;,!R-K4PZR0XM_M/:'"/BEYF8'
M@]AXQPX=$$#%1',0\DX)/I"Q`!X2G"#&$#<LP4`+)+S```-41-E``$)4Z2DO
M/@7`0A)$,%`7A]A].5X.;1A`0``U="K(G(FX<*</B-#J1IR(_D&KKZM=(.P%
M"/1I8PD(;/#&1`$T4@(9`:`@P1,69*!""I62=X,8!$S`Q:?@ME*"!Q7$\,`(
M))P[@H9Q45;%`%W(JLF;K,$GP@5\9B)"OB+8VD$5(XS01IZ$Y"A"G()D88`%
M#`AW!'!T%%"!@^%6_`G_#0I`D()&'++!1@(C2&&'$5=`,<&+$X"@,AXLM\S$
MK*YU0*PA'2!,2`T]@,&#.XTL$,P#%'SBP`8W#/@`#);B,`8?'9@@\P$'-&T"
MU`?@&[4;4#====1_3(TOGUE/?0?479MP`=D=R&R""6.;@$#34EN1]053'S`U
M`DZ?[3349U?=]-LRGYWVU'`C$+:P4>,=-=2&.^TUU'>L#;73BEOAM=A0BV!W
MWW^DK7?G-580!'@BP3!"2".`9T0;%9#1HHL=[%%`"!&0<)5"XZDP8!`._"'$
MC0B\)VS!G1<K2,TW*Z`A`RA\+<@%JQ'RQ`MOT+'`GX7TFBO!/>U01P`27$$%
M_PPP?!>!`F2(>ZAK=-[SNB#OU^/B(&&,$8)U7CZ4P@M>>,$`ZV%('R)LP('1
M/<P+'$L7>$A``CM(X`]<P)4;[$.(X;GA'0?+H)YF9(8;;&0#RTG-(-)VL#1@
M8`8M($#TLG>\&>&K)P<SU`[F\[TY0(`!+Q`&E/!0!HOY,!%94(/NPO.&%R0`
M!F^``15"0``;*&)<%&!`$KW`AAM@8P`6&$`U+/`"*-3I4(YXVKV>)@@AL$`*
M,ZA"LP1Q`,W]X0(V.D`#V``#"+3G$/T2!(L0`$<1K(%%W#-$"<)`@"](T3$1
MX$`(?\C($D#A`?F#P76$DRX6+%(1/2#"`R`3!"V<`?]7A-C!'EI#`!G\H0PE
MX)H("-?&041N7X@8&Y\^\!T%O)&"A;#!!\13@$OX8'B#6,/Q%!$&`&#F#2D(
M01CFQ\A/D8$**:"*_@J4@@?8LA$[F$.&5"``P0"/13BI@0!I1,Y!N"$->\"/
MC1CQR#=\X7=Q8@(8,B",!B1B!VM()3!CV"<1^@IA#K``%:C'!@Z<H9D5*P,'
M(#""[WA!(@6:000(\#)"O$US:4M<!0:5`@C(X%MWPI'!YF.KYQFOGS1;Y0AO
M!`0JS"`#O>M<1N_0@3,D`2-#8),@WQ&\._`Q-6Y#7$E[PLQ$@4`-P'F`&L*`
M4'`1@`$PN,S#:H$0!=A33P7_(Q8?$4"&'Y`@`52X:FKP@P!A"BMXOO(!?I#7
M.7QISC47V!<"6!17?+&(K0`0DQ-J\(>YSE4$")#`N>S``6:FQHDXNE,'2@!'
M&R%@3OG:02!QY(`0<"@!"I!74R,4@@_)@Z#\VP`9;!9*_#1`!99Y`O?PU-?H
MH;4$%57L'W3``QXXX!UI,UY<"3$!,&0!#'*840^L@X$'%@(+&Q`)`V+ZAP!4
MH`A%:)8,3B``/?P!#`(H0A<$X("3#@((!!!`%Z([V3N)(``X@`P5\+#9*EGG
M#22I"`E&$(%+_O1X!S#6'R@P`Q)$``2"',0%W)`((%`@"1D8SQ(R\`0PH)40
M7."!_P8N]``I1,`)#B@#%RR;``T8`@Q5T(@8F%`#"6A@(4Y2014X0(1K-0$(
M!8A`"I80!+X2P@,YD((7IF``URD"#QE`%PO:&Z$R1/,((V!#0UN0@$+%1T^?
MNZ4)X`<`.[#A"PLHQ!W>`4<!KZ%JP>O``4Z@`I$PD,DI$.T?VAC7`TP@"6S8
M7PN*J`(*F*$$"G@#&S+@@55V('("P&$"*B`$`6!@26QXR@O(,0,[7.$/$QC#
M$NQ``@X8[@!WB$,6V#`#-G@Q$5B8CP<TP!TG$]DY)4B=8^S@$!)D`7Z-N``0
MD+0$&KAH`DC(]3IRC80FZ,!&(DC#`%1`@@,Q@`Y+F(%P<O^P1@24P0E&4/8;
MI%`=D;`!`RCH000@4P3X?``R#/#`!JQSF6-CP(@H8>`'>E(&"F"+"D$3!`N"
M<80G]+`1`B""'4Q]ZN9$H$`Y?`H*905*MNH1EPBH@1&\$`$P%&(!$)""Q"<N
M\9000!!S(`$,EF"!,8"`!GV@0`1@,(,0O/H/\SY"'<<@`S,TP`G03$$$>@``
MX5C`QG_PF1T><`4),,`B-^A"R\W`@1QH7)(A&(000I"9%@C@#PV@`AOL,("#
M*N(.H'3``!S8;^?<`0`:;W0+1*("&^.DKG.-ZUWYY($()."_ABJ"ERB-D>MH
M/`%/^(,#KK4$*%C]3B4``3VE,`#_+@"A"C-XP!1N.X@R2&`)&'E"'_HG!23L
MZP(4@`P=\``!C7]AC8-8P!2\4W)"=%#95.B!9??7@TOT(`<W8&[7"T.#HD6$
M?]6\>`EL4`(^(4N#>A2$!X)``BJ``*0]X0`5<O`5"%B`^3=`YA=TP`&1.`$1
M`D#R$B8@@`VI`/2-;P(=[%"%+`3!#B-P@@T08(4@Q(0`#CC7`(2P0D&@8`G7
M2CHA[D\9.I@N!1S0"%;`!280!S$@!7U@6+.7$T*@`#>@(0^P,?MF48?P8'^`
M!3B0(`)P,JE1!%K@4S)S,#60?2/P`6;P`R/`=8<0`-="`F$@!I@!`8AE*&EP
M?E10`09`_T\6<#(+T`(R5P-%D&0*T#ZF5P6)-@2%8`4#@&016!Q99@EF4`41
M@',+2!BPU0!HU",JQP`-,$/P@TMZ=",E,`=V\`)3`'YAT$-H=3`=,'D)T`9%
M8`0RQUPB0`!BD`=B,`<_-P(H<`4C``,`D".[50(%8`<J,`9"8`$A(P%<P`*F
M<P4BX&Y+<'&'P`5^6'J&@@<:X`4-E0,.QP@E(!AG\`0&\'=52!@'4P(RP$4G
M\0(>=0?UP5BI5!\4!$M_(`-CYP4*@'SW,0A]$&<Q,`92``,9\(1_(`!24$1>
M0#Z7@0*K!P#PT0'JQ`&/T4L5$!<?L`!$D`!+(`$E0`%VP(6((/\"5W`=^D<(
M"U``RS@"0:`$I-4G=Z`$!B`!%'.*A;%.?Q`&3Q`!C6$9-S`'<0"&A.!3@^`!
M`[`15*`$C$``1A0#%9"!#&!*&,=JIM,"=1$!#I!7,U!X/2&0TU-0?V`#,A8!
M,=`PRO0'U-@"A14G9#``\G".\*.'DP$#+;!XC'`&,M`%-&"/5;(#`<`!-T!$
M*G`%`?!"A1!#<P5U#&`'*3`%(""(,S)7##D#,;``_&4'%/`MV30`''`"77D"
M)P!@'.`ER_4\J1$H#Q@!2.`K6@`<+Z`=`O`M-!!G&E`&H$0(!+`4,("$A"!8
M1_`&.0!57J`&''@()3`!,A``]\:3S-'_+\A""#U`!8XA#QM0"8P%6'0S"&@U
M:G/W!3I%5\B"``R9`C%0!@1`/CE@F7.``I%3?Z<U$040/6,#!#?E!3LH"$KP
M`-S1/Q(I!$N0``P``E:P6GDP7\GT)D(0`SF4`E"@!DQ)`A60"'=0!W?)F,X!
M6(4P`2R0`QE0;!#``CV`=JF17X/P>D?`E&IP`C(@!_G297_`D`D0`Q<8E"\0
M`E!@!610!O1"""&`&5+``F=`GB#P`?#U!BP`4CL``1LQ`B'`)AO`/PS@!(5)
M!@70`C!0"Q^P98)P`N$Q`F+P!R@P/B1@`>#'!&'@`*9HG<Z!2V#(!7=``Q2@
M!@PP`W3P!!60_P:&X%9<,`%.8""0@0$6$`-?,*0;4*1)D$-M(`A1!QYL8`$;
MX`1BX`0*,*4*,`=W)@,YX!$JD`,Q$`,?(&.-%@-4J`7+F8"#,`$Y(!(IP*5/
M$`.=MXP/<XX@,"@M<)M_``4W\!TA4`%*0``24`$RL`"XX@`"H)""8`90(%:6
M,`<4,(.;P`5F,`9C``6R9PD"```ZY0B.5`0G(P02P*FN8`,LL(O`\HZH<0!G
M)PA<\`X[@`42X`17D`-5\`0"T`/U85*#@`444#0BL2P;HQ&2-`,J\(:"4`9:
M$`']Y06;1#K],R!)8`,[@`)/0&P[IVP:P0!JL`#P`0+(2@?C]$8H$/\$DH0T
M+]"$##!R;T`/97`&%D`^`V",-N``4'4$1)`$!E`!B_D'NO$!+S,!]S-DE\`%
M00``U:D)4""K-Y!([W@(92`&%N"HCF`&#(`!"BFQ1G!RK%`#,9!T??`$)V`S
MT4,OC/5D..(#-5`!3W`#.:`&'.``>^`BAUD`21`!*"9Q;%`2+]`8-P!@@@`"
M`'`##+`$2_``^*<"4M`";,"%J,0%!``!`\4`;!`!;=`#!1N23N`%!E`(]C$!
M$J`&A[8_'%<!4$`%%08"QWH5-\!4A4``4_`$,D"%@X`";$`$0%`"=`$!-6`&
MI>$`\V$%+B<#3`4$(%`:(G`&%>``-H`"".#_`"C`7(S;`/ETF`V``B!P$ZEQ
M`T:P`$!``\L4!H/;++L'`A/0``Y``R?#!&9@!C:0F"7@`+!B&HBU``T@`Q,0
M`!/@&@0PHD#PGBDP`'$``KU3`F=@!F5`!G@@NXHYNHQG`X.+!V?00X![!ILR
M'S;0`#JP``/@!7G@N0(TO/.A3R/41O<"/\S$!0[P`Q'P!3W@``Y"1JF1!1L`
M!W"``S@POSB@`?(+!RLPD!Y0`$%`OW#P`_,+`1KP`P80&,*W`@+\`TA0C]E3
M`5.PDXA@!4V0!#CP`_L;'P0`!SGP`S\`P)183B2+"&!`'A.P!=-#`0Z``RI@
M!`:`"S*``VBQ`E@`_P5P@`%1<`<$@`-*@`)&$`8*P`!9^P<>\`4JP#PV8`-C
MH`)L$`03,"-;$`%3^#HVX`11X`4?4+<-@`,%<&4:$)UX``=?<()%(`0&\`-C
M@`%/`&`>0`%&8`3_401#!04)H'\G8`<A4`8QD+4EH`4;(`05H+]&(%H&@`$;
MX$19@`-V0`0KX`$V@`,KP`)5\*S7Q<!78`1'$`4&@`,H$!\L\`,DY29&B9VS
M\HY80`,$T`1:T`19L!Z&"8O`5R/>A"A#)0*K>@A,H("&,A]85U>J`6N&XDUZ
MLD+SD93O>`9+@`'+$`$&,`&$6@0YP`9%X',0X`1.4`1)D`)J0`%Y(`3\*/\#
M!3`#<+`!.,`&-5`'.3`%`I`'`,@!*L`!!%``HS4(`/`"02#/-J``55``4``!
M3P`$+/`"./"D=N`$6/`$*U8$W"0#-P0`'R!S:9`'+\"HF@0%(H`K(O`#;Y<$
M`Y$`!2`#,]!+3"`.0-`&;*`&7Y``4-*?%Q<`8R`!B-<'9N"*&_`!+U`$93!O
M('`"XR$&/C<'.]`#+U``JW4VA9"47U@"PI0('D`#OP4&.F`%"_LBK3!#(F`%
M9W<O&`2*ZC0EQJP(-4`$7D`#".T`.]``!;`!:2H`'T`%8?`M#3`#5Q!3-:!B
M#@"#62`$6M`"5FD'&R``!I``8A!H5Z`$6(V.3[#_!"2P`C1`!QK``0LU`'B`
MOCNY`B2C!!@P!EC@!,%9R&K@`0T@#"C``"'0&E_P`F(E`C^G!A^@G"E``"?@
M!:84!@PV`0I1`0'@!41``SW@0%P@`RR0!U&0`%#0!`[D`B"@`EJ0D1'@`36P
MIB><`P"@`^(30L7<)R?U5WPTLKZBRSCR.YLP5.8%"EZX97>@62&U""6`'SL`
M2OV2+W52?X10!B&0``(0,7\0F4\`!=NF!!80!"%$QWT@*Q5``B$P`4%P`X*@
M`"3`!5&`QS&0!#'01&/0)!];"%P0S@,@`6]0#E_P`^D@!4.`*V:@!@.0!Q'`
M>[3CKUXP!G\@`3/0<7;@_^)_T`;-33_T&ITZD`)1``)BH,PHR4T]<`0:L`!-
MD`):4`,KD`)F(`&9(@'\B(,/4+=RE\I5D'1:X`4`<!,A<,]+0.-U\D;870)3
MEAKW!3.#X#2MP$\H50@'X%WJ/2,N8"]]^PBX\,MI]4]$52-Y,#(#D#Y/\`#^
M<+/^F@("$``!T`,I0`6''@`GD`(&0-L;,!\#$`%_$-ACX,RY'``+L`)VD`2R
M<@<G$`!F4'-Y,%P%L``U\-9]?DTOB`%T$)TX%@(+8`0D8$^!30%Y^00.``4J
MH`9XF0(JK*\)D.33@P(-(-:B8@=B(`)/P``!8`-/0`5F@`-+P`-/%7LQD`$]
M\?_H#B#1MF33`'`R!L`&=!`$BWDC)@`HA&!P?05,=W(!:B4NJ[&&B;!;C,`%
M<1(U^%Y>B:"?@^`#Q>*%B)!Y7N!D',`&&@`!ED(&*X!#&*`&+9D"UY;6"=`'
M#=`"*S`?1&`!?P`$Q_8%:F0%4P`@*7`"..$#:*%O*D`#'A`"*A#`J8`#]CT(
MX#@%?!4&###7&``#60;S$C`!`_``45`%&'`%K@$%(]`'MG+'?8`&=UP=5$`'
M=ST#03,`55`#+U]C!B`%27!#S.8-(9D'*N`!0P`#!2`"3I`"4K`!?X`$%`'4
M`?]3",/=[\XGPF*+;P3GGA"*SS,COZ*U;T-3'<!'57/_-O`^,V^4(S43^(>P
M`_+"!($D+"5PV(;0`Q0P!S%%!B>0!XFA!4+@J@"0!P3`!6$P!QN@`#30!=N+
M,1S(S_:7!S'@!"[0;J,/!;LK"%O``D^P`2=@J`[@!$_P!!(@!&/P!&$P(QA#
MB3R*`J?O!$)0:"N0930P!R?``G7F&G@@!FI;`13`5&3`S1(`!2>`!0(P!V+)
M`4)`0`10!OVK`!60#A-P`M$I!`0P9&.@^B)@1CX-"']9,S<..W^((A<=(@B(
M"!T'B"4=)9*(B!<7F'\E/IR@H:*CGZ`[3"68C)NCH'<'.YH7BB*B(C:MAR5I
M"`B+%VZ]FIUWK2*UG8<[J<:'_W_%K9-W(B4[RLS1)274)=`[7*'.R'\BT#(4
M$@(#&0W199C3V*+5HR5<N-N)G-]A+#@0'.254O0'`39&F$1TZ,3JV)\.F[A0
M6G0`$L1?%PYH@JBP0Z2-R+;\T20BV!\AJ1I%$U7&V4-'HA#<V3'.%$HW%Q!<
M&@F3V,I$AWS(:Y4/$;2?2"<YZP9O:,).-1L$B7##`H&D6%>^RU8APA00+B<Q
MS52S1,])$$VHQ%2F9M90#C')-"MBBQ""CPYL0W",;Z.X98KU1&"B@XD#=_;,
M*E&GWDJZ(G:L<1IJC:ZP]8[^P?PVVBU.VFPQH[:OLVE5:9YMK4=:E%`WY)#U
M95C"1'TBMQIC__'!N7-.'P=JSDJ44K8F7ZLZ^`)5Z=C">B+ANC@[B:^O7G_*
MK"::LG>H.Z5V4SX-RHI+FJ+N,)M)OCVB'=!"NR^)P(VBG6B7B\KI'FZJ2J$(
J-9);6`TW"BNB2,0(@)-4A&`R/Q7US'C-](?4'6@\%IZ%IS%!8%*!```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
